Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $10.93 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.